diabolically unsophisticated sharetraders, page-37

Hey this is very interesting!!!
The top 3 VLA postings since 27/04/2007 are:
1.) Mr Deeds 23/09/2009 490 readers
2.) Vespasian03 27/07/2008 402 readers
3.) TassieTwo 27/07/2008 398 readers

Here they are:


Tassie Two 27/07/2008 (398)

VLA holders may be interested in the coverage given to Viralyics by The Ausralian Investor 26/7 in their daily stock news release . Makes one believe in the considerable potential VLA and its viral products have despite what the ASX thinks.
Cheers
TT


Vespasian03 27/07/2008 (402)

Thanks for passing that on Tassie Two...here is part of the article for those interested.....huge potential here as a few of us have been suggesting for a while (including that old hand "The Speculator") Cheers
"Can a sneeze turn out to be a potent weapon in the ongoing battle to find a cure for cancer?
Yes!
In a quiet corner of the University of Newcastle, Associate Professor Darren Shafren and his associates have been making remarkable strides towards, if not a cure just yet, an improved quality of life for those suffering the effects of terminal cancers.
Shafren is the lead scientist for a publicly listed biotech, Viralytics Ltd,( ASX code VLA) and has been working on the company's internationally patented "Cavatak" virus since 1999. That's right, a virus. To be specific, a common cold virus. The field is known as oncolytic virotherapy and its benefits have been known for decades. Only recently however has it come to the foreground of the multi-billion dollar market in cancer cure research.
For the last century there has been anecdotal evidence that viruses have the ability to defeat cancer. There are many incidences of cancer patients being exposed to viruses and having there cancers spontaneously going into remission. It is only in the last decade that science has developed to a level that it has gained an understanding of this process. Virotherapy is now a recognised leader in this field of research. It is hoped that one day patients will have a choice of treatments chemotherapy, radiotherapy or virotherapy
Viralytics under the science direction of Professor Shafren is at the foreground of these developments. Professor Shafrens’s work has been peer reviewed in many prestigious medical journals. The company has a scientific complement of 15 staff at Newcastle University and a tightly controlled and small, administrative staff led by Exec Chairman, Bryan Dulhunty.
The bar to commercial success is not high. The Company does not need to cure cancer, it simply needs to extend life. One of the significant potential benefits of virotherapy is the improvement in patient quality of life. Current treatments such as chemotherapy, radiotherapy of surgery are either toxic or invasive. Virotherapy holds the potential to treat cancer with minimal side effects. If this potential is proven in humans it is likely to become a treatment of first choice
How does it work? All viruses work the same way. Every virus has a unique receptor that attaches to a unique key that exists on cells. It just happens that many types of cancer cells have a preponderance of keys that the common cold virus (CAVATAK) uses to attach itself to the cell.
The virus once attached to the cancer cells injects itself into the cancer cell, takes over the replication mechanism of the cell, multiplies and literally bursts the cell apart delivering thousands of new viruses to go and infect other cancer cells.
The company has 5 families of viruses under development. CVA 21 (CAVATAK) CVA13, CVA15, CVA18 (all with major market patents granted) and EVATAK (patent application pending)
The Company’s lead product is CAVATAK is currently being trialled in multiple human studies. CAVATAK research is currently being conducted in the areas of prostate, breast, melanoma, multiple myeloma and glioma(brain) cancers.
An initial Phase 1 trial has been completed and multiple other trials are currently underway at Australian hospitals.
Summary of the trials:
Melanoma trial – direct injection into tumour
– First in Man Studies
• 5 x stage IV patients received intratumoural treatment
• Single dose range from 7x106 to 2x107 TCID50
• No drug related serious adverse events
• Treatment well tolerated
– Phase I Intratumoural Trial (in progress)
• Dose escalation study from (2 doses x107 TCID50)to 2 doses 109 TCID50)
• 3 cohorts of 3 patients each – completed first cohort
• No drug related serious adverse events
• Treatment well tolerated
• Presence of viral genome noted 4–5 weeks post injection in some biopsies
Prostate, breast and Melanoma – intravenous infusion
– Phase I Intravenous Trial (in progress)
• Dose escalation single dose 106 to 4 doses 108 TCID50
• 13 cohorts with 2 patients per cohort
• First cohort complete
• No drug related serious adverse events
• Treatment well tolerated
Future trials are being planned.
The Company has also received orphan status approved by US FDA for stage II-IV melanoma which allows a fast track product market approval
PRECLINICAL DEVELOPMENT:
The company has started negotiations with the United States FDA for design of toxicology studies suitable to allow Phase II trials to be undertaken in USA.
MANUFACTURING:
The Company has announced the signing of a contact to commence production of Cavatak in a USA based facility to world regulation standards that will allow the commencement of Phase II trials in USA as well as the production of virus in commercial quantities when required. The Company currently has sufficient virus stored for the completion of it current clinical trial program
PATENTS:
Patents have been granted in the major world markets of USA and Europe (Notice of Allowance) as well as Australia and New Zealand for Cavatak as well as for CVA 13, 15 and 18. Patent applications are pending in other world markets for these viruses as well as for Evatak
RESEARCH and PUBLICATIONS:
The company's website lists all peer review journals chronicling and acknowledging Professor Shafren's work, the most recent being in the American science journals reporting upon developments in the fight against breast and prostate cancers.
COLLABORATIONS
A Collaboration has been entered into with Professor Abjiit Guha. Who is co-director and senior scientist at the Arthur and Sonia LaBatt Brain Tumour Research Centre in Toronto, Canada. Professor Guha is also President of The Society for Neuro-Oncology in The United States. The Australian research is led by scientist Dr. Gough Au
Dr. Au has received a significant grant from the National Health and Medical Research Centre (NHMRC) here in Australia, to continue his collaborative work with Professor Guha.
COMMERCIALISATION
The company is ready to enter the next commercial stage of returning shareholder value. Nine years of research; international patents approved; international collaborations; debt substantially reduced; cash burn halved; acknowledgement in peer level and business journals (currently part of The Speculator's portfolio in Money Magazine) and the science under Professor Shafren's guidance, grows apace.
In the past 24 months the company has completed a significant restructure.
Management has changed the Company from an entity with complex related party dealings with high overheads to a clearly focused clinically driven company. It has significantly changed its historical shareholder base and is now in the process of selling down its historical passive investments
It has appointed new directors strengthened senior scientific management; appointed key scientific advisors and international consultants. Under Mr. Dulhunty's watch it has reduced the annual loss from $9.3m in 2006, to an estimated $3.5 in 2008 and reduced the annual cash burn from $5.5m to an estimated $3m.
The Company has a business model of employing a small core team of professionals that cover the key areas that the Company must deliver on then engaging outside specialists as and when needed.
The bar to commercial success is not high. The Company does not need to cure cancer it simply needs to extend life. CAVATAKs natural ability to be non-toxic and non invasive will it allow to provide a higher quality of life than existing cancer treatments. If this potential is proven in humans it is likely to become a treatment of first choice.
The Company aims to enter into a development agreement with a major world market leader however until this step is achieved shareholder value will be enhanced by the announcements of clinical trial progression and success."


Mr Deeds 23/09/2009 (490)

Hey,
I buy shares at 2.5 and 2.6 cents recently and sell some back at 3.3 cents amid the flurry yesterday (a profit is a profit!!!)
So who is this this ******** selling at 2.8 cents this morning!!! Talk about killing any momentum!!!
What on earth are they thinking of!!!
("Lets buy some shares at the highest possible price and see if we can try and sell them for as little as possible ; what fun!?!")Excuse my sarcasm!!!
Cheers